Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.34 |
| ▸ | FEN1 | P39748 | 3/20 | 0.34 |
| ▸ | CCR1 | P32246 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15462392 | 1.00 | KMT2A (0.40) | KMT2ATSHRLMNACHRM1AKR1C3 | |
| SCHEMBL15462515 | 0.91 | CHRM1 (0.41) | KMT2ACHRM1AKR1C3NAAAALOX5AP | |
| SCHEMBL14815880 | 0.91 | CHRM1 (0.41) | KMT2ACHRM1AKR1C3NAAAALOX5AP | |
| SCHEMBL14815967 | 0.86 | ALOX5AP (0.39) | CHRM1NAAAALOX5APFEN1 | |
| SCHEMBL15462405 | 0.86 | CNR1 (0.43) | KMT2ATSHRAKR1C3ALOX5APFEN1 | |
| SCHEMBL14815747 | 0.86 | TSHR (0.43) | KMT2ATSHRMAPTALDH1A1 | |
| SCHEMBL14815542 | 0.86 | CNR1 (0.43) | KMT2ATSHRAKR1C3ALOX5APFEN1 | |
| SCHEMBL14815836 | 0.86 | TRPV4 (0.40) | TSHRLMNA | |
| SCHEMBL15462481 | 0.86 | TRPV4 (0.40) | TSHRLMNA | |
| SCHEMBL15462466 | 0.86 | TSHR (0.43) | KMT2ATSHRMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1D, CACNA1A | KMT2A 1876/4885TSHR 1272/4885LMNA 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.